Deutsche Märkte geschlossen

Novartis AG (NOVN.SW)

Swiss - Swiss Verzögerter Preis. Währung in CHF
Zur Watchlist hinzufügen
83,03+0,92 (+1,12%)
Börsenschluss: 05:31PM CET

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—General
Vollzeitmitarbeiter108.000

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Vasant NarasimhanChief Exec. Officer4,87MN/A1976
Mr. Harry KirschChief Financial Officer2,71MN/A1965
Dr. Klaus Moosmayer Ph.D.Chief Ethics, Risk & Compliance Officer1,32MN/A1968
Ms. Karen L. HaleChief Legal Officer1,98MN/A1968
Dr. Robert Kowalski Pharm.D.Chief People & Organization Officer1,14MN/A1968
Mr. Steffen Lang Ph.D.Pres of Operations2,25MN/A1967
Ms. Marie-France TschudinPres of Innovative Medicines International & Chief Commercial Officer2,46MN/A1971
Mr. Richard SaynorChief Exec. Officer of Sandoz1,79MN/A1967
Paul PenepentHead of Group Financial Reporting and AccountingN/AN/AN/A
Dr. Samir Shah M.D.Global Head of Investor RelationsN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CHF.

Beschreibung

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Corporate Governance

Novartis AGs ISS Governance QualityScore, Stand 1. November 2022, lautet 2. Die grundlegenden Scores sind Audit: 2, Vorstand: 2, Shareholderrechte: 9, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.